Table 4 Analysis of mediators according to ICS and/or LABA use and ICS dose categories
From: Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β
ICS group | ICS/LABA group | ICS dose <1000 | ICS dose <2000 | ICS dose ≥2000 | P value | P’ value | |
|---|---|---|---|---|---|---|---|
N | 6 | 74 | 24 | 19 | 37 | ||
gal-3 (ng/mL) | 356 (293,471) | 274 (166,471) | 318 (210,493) | 289 (162,420) | 273 (163,471) | 0.454 | 0.526 |
gal-3BP (ng/mL) | 43 (25,115) | 71 (27,161) | 58 (21,158) | 75 (23,196) | 71 (33,142) | 0.559 | 0.930 |
gal-3/gal-3BP | 10.3 (2.4,19.1) | 5.2 (1.7,10.6) | 6.2 (2.3,23) | 5.6 (3.0,9.3) | 4.7 (1.3,9.5) | 0.352 | 0.501 |
IL-1RA (ng/mL) | 80 (67,233) | 176 (103,288) | 200 (97,323) | 161 (111,286) | 162 (102,271) | 0.100 | 0.855 |
IL-1β (pg/mL) | 1 (0.6,3) | 156 (3,694) | 157 (2.8,734) | 53 (1.5,732) | 157 (3.5,603) | 0.030 | 0.733 |
IL-1RA/IL-1β | 73 (35,122) | 2.1 (0.23,41) | 3.3 (0.3,43) | 5.34 (0.2,90) | 1.1 (0.2,26) | 0.144 | 0.755 |
IL-6 (pg/mL) | 447 (397,502) | 337 (169,1186) | 501 (311,1140) | 400 (197,903) | 326 (178,1195) | 0.770 | 0.874 |
IL-8 (ng/mL) | 14.7 (11.0,40.6) | 17.5 (8.5,50 | 18 (11.5,56) | 25 (7.2,51) | 14 (9.3,31) | 0.985 | 0.819 |